Clinical trials of the new drug, APPA, can now
be initiated as pre-clinical trials have shown its effectiveness in relieving
OA pain and improving the functionality of OA patients.
Osteoarthritis (OA) is the common degenerative condition of joints which causes breakdown and eventual loss of the cartilage creating stiffness, pain, and impaired movement of joints. It is a globally affecting disease which is the leading cause of joint pain and stiffness in older people. Many researches are going on to find out better treatment for this chronic condition.
A clinical trial is in process on a
promising drug for the treatment of osteoarthritis, which has been developed by
the collaboration of The Liverpool University and AKL Research and Development
Ltd.
"The 'holy grail' of anti-inflammatory targeting of
neutrophils is specifically to block their tissue-damaging activities, but not
compromise their ability to protect us. Work is ongoing but to date it appears
that APPA does not target the host defence properties of neutrophils but does
block their pro-inflammatory activities."
There remains a high unmet need for an effective, well
tolerated OA drug, so understandably and there is much excitement about APPA’s
prospects.
American College of Rheumatology
https://news.liverpool.ac.uk/2017/02/17/clinical-trial-for-new-innovative-osteoarthritis-drug/
Clinical trial for new innovative osteoarthritis drug
Professor Robert Moots, Professor Steven Edwards
Comments (0)